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ABSTRACT
Background: Studies comparing percutaneous and surgical 
methods for the treatment of the patent ductus arteriosus (PDA) 
are rare in the literature. This study aimed to perform a com-
parative analysis between both PDA treatment methods with 
emphasis on efficacy and morbidity. Methods: Observational 
study with 2 cohorts of children and adolescents > 5 kg and 
< 14 years of age with PDA, treated under a study protocol 
to assess the incorporation of novel technologies to the Bra-
zilian Public Health System (Unified Health System – SUS) 
at an excellence hospital, in partnership with the Brazilian 
Ministry of Health. A prospective analysis was conducted for 
the percutaneous group from 2009 to 2011 and a retrospective 
analysis was performed for the surgical group between 2006 
and 2011. Results: Eighty patients were included in the per-
cutaneous group (60% female) and 39 patients in the surgical 
group (51% female; P = 0.37). The median age and weight 
of the percutaneous and surgical groups was 39.4 months vs 
25.5 months (P = 0.04) and 14 kg vs 11.1 kg (P = 0.052), 
respectively. In the percutaneous group, 78 patients (92%) had 
type A PDA and the minimal ductal diameter at angiography 
was 2.5 ± 1.2 mm. Amplatzer®, Gianturco coils and Cera™ 
were the most commonly used devices. Clipping was the most 
commonly used surgical technique. The success rate of the 
procedure was 100% in both groups. The surgical group had 
higher complication rates, including chylothorax, infections, 
transfusions, systemic arterial hypertension, use of opioids and 
a greater need for intensive care. The median hospitalization 
time was 1.3 days in the percutaneous group and 7.9 days in 
the surgical group (P < 0.01). Upon discharge, occlusion rates 
were similar in both groups (91% in the percutaneous group 
and 87% in the surgical group; P = 0.71). Conclusions: Due 
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ReSuMo
Tratamento Percutâneo vs. Cirúrgico da Persistência  
do Canal Arterial em Crianças e Adolescentes
Introdução: Estudos comparando os métodos percutâneo e 
cirúrgico no tratamento da persistência do canal arterial (PCA) 
são raros na literatura. Nosso objetivo foi realizar análise 
comparativa entre os dois métodos de tratamento da PCA, 
enfatizando os aspectos de eficácia e morbidade. Métodos: 
Estudo observacional com 2 coortes de crianças e adolescentes 
> 5 kg e < 14 anos, portadores de PCA, tratados durante um 
projeto de avaliação de incorporação de novas tecnologias 
ao Sistema Único de Saúde (SUS), realizado em um hospital 
cardiológico de excelência, em parceria com o Ministério da 
Saúde do Brasil. Foi feita análise prospectiva no grupo percu-
tâneo entre 2009 e 2011 e retrospectiva no grupo cirúrgico 
entre 2006 e 2011. Resultados: Foram incluídos 80 pacientes 
no grupo percutâneo (60% do sexo feminino) e 39 no grupo 
cirúrgico (51% do sexo feminino; P = 0,37). A mediana de 
idade e de peso dos grupos percutâneo e cirúrgico foi de 
39,4 meses vs. 25,5 meses (P = 0,04) e de 14 kg vs. 11,1 
kg (P = 0,052), respectivamente. No grupo percutâneo, 78 
pa-cientes (92%) tinham PCA do tipo A e o diâmetro mínimo 
do canal à angiografia foi de 2,5 ± 1,2 mm. As próteses mais 
utilizadas foram Amplatzer®, molas de Gianturco e CeraTM. 
A técnica cirúrgica mais utilizada foi a clipagem. A taxa de 
sucesso dos procedimentos foi de 100% nos dois grupos. O 
grupo cirúrgico apresentou maiores taxas de complicação, 
incluindo quilotórax, infecções, necessidade de hemoderiva-
dos, hipertensão arterial sistêmica e uso de opioides, como 
também maior necessidade de terapia intensiva. A mediana 
do tempo de internação foi de 1,3 dia no grupo percutâneo 
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to the lower morbidity, the shorter hospitalization time and 
similar efficacy, percutaneous treatment of the PDA should 
be considered the modality of choice for selected patients.
 
 
 
 
DeSCRIPToRS: Ductus arteriosus, patent. Heart defects, con-
genital. Surgery. Heart catheterization. Prostheses and implants.
P atent ductus arteriosus (PDA) is one of the most frequent congenital cardiopathies, accounting for up to 7% of all congenital heart disease.1,2 Its treat-
ment is indicated in the first year of life in the presence 
of heart failure, or later when there are hemodynamic 
effects characterized by increased left ventricular di-
mensions on echocardiography.3 The timely closure of 
PDA prevents the appearance of complications such 
as heart failure, pulmonary hypertension, arrhythmias, 
and possibly infectious endarteritis.1,2
Surgical correction of PDA by lateral thoracotomy 
without the use of cardiopulmonary bypass was intro-
duced in the late 1930s, and has been used with very 
good results.4 However, this approach is associated 
with significant chest pain and a hospital stay of three 
to five days and results in a permanent chest scar. 
In the past 15 years, percutaneous treatment of PDA 
with latest-generation intracardiac prostheses has been 
performed with extreme safety and efficacy in various 
age groups, excluding newborns and young infants 
weighing less than 4 to 5 kg.
There is a scarcity of comparative studies of per-
cutaneous and surgical treatment of PDA. Although 
the few published studies have some methodological 
limitations, they unanimously demonstrate that the 
percutaneous approach has an efficacy similar to that 
of the surgical approach and is associated with a lower 
incidence of complications.5,6 Thus, percutaneous treat-
ment is becoming the method of choice for the treatment 
of congenital heart disease in most centers worldwide. 
In Brazil, although there are several observational 
studies reporting excellent results of percutaneous 
treatment of PDA with different techniques,3,7–9 studies 
comparing percutaneous treatment with surgical treat-
ment are nonexistent. This study aimed to compare 
the safety and efficacy outcomes of percutaneous and 
surgical treatment of PDA. The study was performed 
in a cardiology hospital of excellence during the 
implementation of a project conducted together with 
the Ministry of Health to review the incorporation of 
new technologies within the Brazilian Unified Health 
System (Sistema Único de Saúde – SUS).10
e de 7,9 dias no grupo cirúrgico (P < 0,01). À alta hospitalar, 
as taxas de oclusão foram semelhantes nos dois grupos (91% 
no grupo percutâneo e 87% no grupo cirúrgico; P = 0,71). 
Conclusões: Em decorrência da menor morbidade, do menor 
tempo de internação e da igual eficácia, o tratamento percutâ-
neo da PCA deve ser considerado a modalidade terapêutica 
de escolha para pacientes selecionados.
DeSCRIToReS: Permeabilidade do canal arterial. Cardiopatias 
congênitas. Cirurgia. Cateterismo cardíaco. Próteses e implantes.
METHODS
The present study was an observational clinical 
trial in which two cohorts of children and adolescents 
with PDA with hemodynamic consequences were evalu-
ated. The costs of hospitalisation and materials were 
subsidized by the government project. 
For comparison purposes, the patients were divided 
into two groups: those who received percutaneous 
treatment with intracardiac prostheses (percutaneous 
group) and those who underwent conventional cardiac 
surgery (surgical group). After project approval by the 
Brazilian Ministry of Health in 2009, each patient was 
assigned to one of the two groups at the discretion of 
the attending physician. 
Before 2009, the treatment offered to patients by 
the hospital philanthropic care project was exclusively 
surgical. The cohort of patients treated with the percu-
taneous procedure was evaluated prospectively, and the 
data were compared with data from a historical cohort 
of contemporary patients undergoing surgical treatment. 
Data from the latter cohort were retrospectively analysed 
after data collection from medical records covering the 
period between 2006 and 2011.
The study was approved by the research ethics 
committee of the hospital. The patients’ parents or tu-
tors were adequately informed of the risks and benefits 
of the percutaneous procedure and signed an informed 
consent for the procedure.
Patients selected for this study weighed ≥  5  kg, 
were ≤  14 years old, and had indication for PDA clo-
sure, i.e., left chamber overload at echocardiography. 
The percutaneous group included patients with PDA 
favorable to prosthesis implantation; these patients had 
no coexisting intracardiac disease that required surgical 
treatment. An exclusion criterion for the percutaneous 
group was PDA with unfavorable anatomy for percuta-
neous treatment. This was defined by the interventional 
professional after aortography using a view considered 
appropriate for assessment of PDA. Patients with low 
body weight (<  10.8  kg) or with large PDA, in whom 
the placement of a device could lead to protrusion and 
Costa et al. 
Percutaneous vs. Surgical Treatment of PDA
Rev Bras Cardiol Invasiva. 
2012;20(3):315-23
317
obstruction of the left pulmonary artery and/or aorta, 
were considered as having unfavorable characteristics. 
Patients with PDA and normal left ventricular dimen-
sions, except in the case of earlier endarteritis, were 
excluded from both groups.
The techniques used in both groups have been 
described in previous studies.3,4 Patients in the percu-
taneous group received intravenous anaesthesia with 
orotracheal intubation, prophylactic antibiotic therapy 
(cefuroxime 30–50 mg/kg, three doses) and heparin (100 
units/kg), followed by left and right heart catheterisa-
tion. Angiograms were performed in left and/or left 
oblique view (100 to 110 degrees) with slight cranial 
angulation and/or right anterior oblique view to better 
define the anatomical defect.
The following types of prostheses were used: 
Amplatzer Ductal Occluder® (St. Jude Medical, St. 
Paul, USA),3,11 a device approved for clinical use by 
the Food and Drug Administration (FDA) of the United 
States; Amplatzer Ductal Occluder II® (St. Jude Medi-
cal, St. Paul, USA),12 a second-generation prosthesis, 
also designed for closure of PDA and approved by 
the FDA; it incorporates some structural changes to 
make it more flexible and suitable for specific types 
of PDA; Amplatzer Vascular Plug II (AVP II®, St. 
Jude Medical – St. Paul, USA),8 a device designed 
to occlude peripheral vessels but also used in PDA 
occlusion in lower-weight infants; Nit-Occlud® (PFM 
Medical – Cologne, Germany),13 a controlled-release 
coil approved by the FDA; CeraTM PDA (Lifetech – 
Shenzen, China),9 a nitinol-occluding prosthesis with a 
ceramic coating over metal mesh, designed for closure 
of PDA of diameter >  2.5  mm; and the Gianturco 
coil (Cook – Bloomington, USA),7 a device that was 
initially applied in occlusion of peripheral vascular 
structures, which due to its high efficacy and safety, 
has been approved by the FDA for use in occlusion 
of PDA. All devices used in this study for the treat-
ment of PDA have the approval of the National Health 
Surveillance Agency (Agência Nacional de Vigilância 
Sanitária – ANVISA).
The choice of prosthesis took into account PDA 
size and anatomy at angiography. In small PDAs (up to 
2.5  mm) and in types A, D, or E, the choice was the 
Gianturco coil or Nit-Occlud® of the flexible type; these 
devices were implanted using a retrograde approach. 
The diameter of the coil was at least two times the 
minimum diameter of the duct, with sufficient length 
to form at least three loops. In the presence of larger 
PDAs (>  2.5  mm), nitinol occluders (Amplatzer® or 
CeraTM) or medium-sized Nit-Occlud® prostheses were 
used; these devices were inserted using the anterograde 
approach. In patients who received these devices, the 
ductus arteriosus was crossed from the pulmonary trunk 
to the aorta, and a therapeutic coronary angioplasty 
catheter (usually Judkins right) or a long sheath of ad-
equate calibre was positioned for implantation of the 
chosen prosthesis. The diameter of the Amplatzer® or 
CeraTM device was 1 to 3 mm greater than the minimum 
diameter of the duct. In PDA types B and C, occluder 
prostheses were also selected.
Following the procedure, patients were extubated 
in the catheterisation laboratory except in the presence 
of complications or difficulties. Patients weighing less 
10 kg were taken to the intensive care unit (ICU) for 
recovery from anaesthesia and later transferred to the 
room or ward. Other patients were sent directly to the 
room/ward after an observation period of approximately 
30 minutes in the post-anaesthesia recovery room of 
the operating room. 
On the day following the procedure, patients 
underwent clinical evaluation that included routine 
laboratory tests, electrocardiography, chest radiogra-
phy, and transthoracic echocardiography to evaluate 
the positioning of the prosthesis and the presence of 
possible residual flow. Patients who were clinically 
stable and without complications were discharged and 
given instructions that recapitulated the classic advice 
for endocarditis prophylaxis. Echocardiography, electro-
cardiography, and chest radiography were performed 
before hospital discharge and at clinical follow-up after 
30 days, six months, and, when necessary, annually. 
In cases of ductal occlusion and cases that showed 
absence of complications such as pulmonary artery 
stenosis or aortic coarctation after six months, the 
patient was discharged from the paediatric cardiol-
ogy service.
In the surgical group, procedures were performed 
under intravenously administered general anaesthesia 
without the use of extracorporeal circulation and with 
surgical access through the lateral route using the extra-
pleural or classical approach. The choice of technique 
for PDA closure was at the surgeon’s discretion and 
ranged from section and suture to ligature with metal 
clips. Following the procedure, patients were transferred 
to the ICU for routine recovery. After hospital discharge, 
most of these patients were followed-up at the service 
that originally referred them.
Efficacy was assessed based on the fraction of total 
occlusion before discharge and/or during follow-up. 
Morbidity was assessed by rates of complication and 
hospital stay. The following were considered major com-
plications: death, cerebral embolism, cardiac perforation 
with tamponade, endocarditis, need for reintervention 
(surgical or percutaneous), pleural or pericardial effusion 
with need for surgical drainage, and need for surgery 
due to device embolisation or arterial occlusion. Minor 
complications included prosthesis embolisation with 
percutaneous removal, local hematoma at the venous 
puncture site, and arterial occlusion that improved with 
anticoagulants. The following were also considered as 
minor complications: anaemia requiring blood products, 
non-cardiac infection (bronchopneumonia, urinary tract 
Costa et al. 
Percutaneous vs. Surgical Treatment of PDA
Rev Bras Cardiol Invasiva. 
2012;20(3):315-23
318
infection, acute gastroenteritis, surgical wound infec-
tion), hypertension requiring drug treatment and varied 
respiratory problems (pulmonary oedema, atelectasis, 
mechanical ventilation >  24 hours, post-extubation 
laryngitis).
Statistical analysis was performed using Sigmastat 
Rankings v.2011. Data are presented as absolute values 
and frequency, mean and standard deviation, or me-
dian and range according to the sample distribution. 
The chi-squared test or Fisher’s exact test was used 
for comparing frequencies, and Student’s t-test or the 
Mann-Whitney test was used to compare means or 
medians, respectively. P-values ≤ 0.05 were considered 
to be statistically significant.
RESULTS
During the study, 80 percutaneous procedures 
were performed for the closure of PDA. A total of 39 
patients were identified in the surgical group during 
the study period. The distribution between genders 
was similar between groups, with 48 female patients 
(60%) in the percutaneous group and 20 (51%) in 
the surgical group (P  =  0.37). The median age was 
39.4 months (8.5 months to 170 months) and 25.5 
months (4.7 months to 170 months) in patients treated 
percutaneously and surgically, respectively (P = 0.04). 
The median patient weight was 14 kg (5–52  kg) in 
the percutaneous group and 11.1  kg (5–59  kg) in the 
surgical group (P  =  0.052).
The diameter of the ductus arteriosus at echocar-
diography before the procedure was 3.2 ± 1.1 mm in the 
percutaneous group and 3.8 ±  1.2 mm in the surgical 
group (P  <  0.01). The angiographic characteristics of 
the PDA could only be obtained in the percutaneous 
group. In this group, 78 patients (92%) had PDA type 
A, and two were classified as type E, Krischenko.14 The 
pulmonary end diameter in this group of patients was 
2.5  ±  1.2  mm. Patients’ demographic data and PDA 
measurements are shown in Table 1.
Patients in the surgical group were referred for 
treatment without the need for catheterisation and an-
giograms; therefore, invasive assessment of pulmonary 
pressure was not performed. None of the patients had 
evidence of associated pulmonary hypertension. In the 
percutaneous group, the systolic pressures in the aorta 
and pulmonary trunk were 82.8  ±  11.1  mmHg and 
28.8 ±  7.8  mmHg, respectively. 
The percutaneous occlusion procedure was fea-
sible in all patients taken to the catheterisation lab. 
Amplatzer® I or II prostheses for PDA were used in 
28 patients (35%), the Gianturco coil was used in 24 
patients (30%), and the CeraTM was used in 19 patients 
(24%). Nit-Occlud® was used in seven patients, and 
the AVP prosthesis II was used in two other patients 
(Figures 1 and 2). Implantation was successful in all 
patients. One patient who received a Gianturco coil 
for PDA closure also underwent a 12-mm atrial septal 
defect repair with an Amplatzer® device in the same 
procedure, without complications. The echocardiogram 
of this patient, performed 24 hours later, showed no 
residual flow (Figure 3).
There were no episodes of prosthesis embolisation. 
However, three patients who received the Gianturco 
coil had to undergo removal with a snare loop cathe-
ter soon after implantation due to initial inappropri-
a te placement caused by the anomalous appearance 
TABLe 1 
Demographic data and measures of the ductus arteriosus 
Percutaneous group 
(n = 80)
Surgical group  
(n = 39) P
Female gender, n (%) 48 (60) 20 (51) 0.37
Age, months 0.04
Median 39.4 25.5
Range 8.5-170 4.7-170
Weight, kg 0.052
Median 14 11.1
Range 5-52 5-59
Diameter at echocardiogram, mm 3.2 ± 1.1 3.8 ± 1.2 < 0.01
Diameter at angiography, mm 2.5 ± 1.2 NA NAP
n = number of patients; NA = not available; NAP = not applicable.
Costa et al. 
Percutaneous vs. Surgical Treatment of PDA
Rev Bras Cardiol Invasiva. 
2012;20(3):315-23
319
of the device, most likely due to a manufacturing 
defect. New same-dimension coils were successfully 
implanted in two of the patients, and a smaller coil 
was used in the third patient at the same procedure, 
with excellent final positioning. In two procedures 
that used the Nit-Occlud® device, immediate high-
velocity residual flow was observed, and additional 
Gianturco coils were implanted, with significant flow 
reduction (Figure 4).
In one patient, there was an attempted use of a 
Nit-Occlud® 4  x  4  mm prosthesis via the retrograde 
approach because of the small size of the ductus arte-
riosus at the initial angiography. After several attempts 
without obtaining good positioning, it was observed 
that the ductus had larger dimensions than initially 
estimated. The Nit-Occlud® device was replaced by 
a CeraTM 8  x  6  mm device, which was implanted by 
the anterograde approach with excellent final results 
(Figure 5). The surgical approach was the classical 
lateral route in 17 (43%) patients and the extrapleural 
route in the other 22 patients (57%). Ligation of the 
ductus arteriosus with metal clips was used in 37 of 
39 procedures (95%).
The need for intensive care during post-procedural 
recovery occurred in all 39 patients in the surgical 
group and in 13 patients in the percutaneous group 
(P  <  0.01). The 13 percutaneous patients who reco-
vered in the ICU were those weighing less than 10 kg 
(mean of 9.2 ± 5.6 kg) with the exception of one, who 
had pneumothorax during anaesthetic induction. The 
pneumothorax was punctured and emptied at the hemo-
dynamics lab without need for drainage. The patients’ 
ICU length of stay was 12 hours, and all patients’ ICU 
stays were uneventful. 
There were no deaths in either group. Several 
major and minor complications were observed more 
frequently in the surgical group (Table 2). In this group, 
hypertension requiring medication treatment occurred in 
27 patients (68%), and blood transfusions were required 
in 14 patients (36%). No patients in the percutaneous 
group had hypertension or a need for blood transfusion 
(P < 0.01 for both comparisons). In the surgical group, 
three (7.5%) patients developed chylothorax requiring 
prolonged fasting and parenteral nutrition. One of these 
patients, aged one year and weighing 7.8 kg, was the 
patient with the longest hospital stay in this group (39 
days); in addition to chylothorax, this patient had a 
Staphylococcus aureus infection that was confirmed by 
positive blood culture. Pneumothorax requiring surgical 
Figure 1 – On the left, aortography in left profile (90 degrees), show-
ing type A ductus arteriosus (arrow). On the right, control aortogra-
phy showing ductus arteriosus occluded with an Amplatzer® ADO II 
device, 4  x  4  mm.
Figure 2 – On the left, aortography in left profile (90 degrees) sho wing 
type A ductus arteriosus (arrow). On the right, control aortography 
showing ductus arteriosus occluded with a CeraTM prosthesis, 8 x 6 mm.
Figure 3 – On the left, aortography in left profile (90 degrees) showing 
ductus arteriosus type E (arrow). On the right, control aortography showing 
ductus arteriosus occluded with a Gianturco coil. An Amplatzer® ASD 
device was used in the closure of the atrial septal defect in this patient.
Figure 4 – On the left, aortography in left profile (90 degrees) 
showing type A ductus arteriosus (arrow). On the right, control 
aortography showing ductus arteriosus occluded with Nit-Occlud® 
and Gianturco coil.
Amplatzer ASD
Gianturco coil
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drainage occurred in 1 patient, and one patient had 
a bilateral granuloma wound requiring two reopera-
tions for treatment. The latter patient later developed 
a cutaneous fistula that spontaneously closed in the 
follow-up period.
The in-hospital effectiveness was similar between the 
two groups. Minimal residual flow at hospital discharge 
was found in 9% of the patients in the percutaneous 
group and in 13% of the patients in the surgical group 
(P  =  0.49). 
Figure 5 – On the left, aortography in left profile (90 degrees) showing a small type A ductus arteriosus (arrow). In the middle, subsequent aorto g-
raphy showing a larger diameter of the same ductus arteriosus (arrows). On the right, post-procedural angiography showing totally occluded ductus 
arteriosus with CeraTM prosthesis, 8  x  6  mm.
TABLe 2 
In-hospital outcomes
Percutaneous group  
(n = 80)
Surgical group  
(n = 39) P
Complications
Chylothorax 0 3 0.01
Pneumothorax 1 1 0.60
Respiratory problems 0 6 < 0.01
Use of blood products 0 14 < 0.01
Arterial hypertension 0 27 < 0.01
Infections 0 2 0.04
Opioid use 0 4 < 0.01
Residual flow at discharge, n (%) 7(9) 5 (13) 0.49
Need for ICU stay, n (%) 13 (15) 39 (100) < 0.01
Hospital stay, days
Median 1.3 7.9 < 0.01
Range 1-3 4-39
n = number of patients; ICU = intensive care unit.
The length of stay was significantly higher in the 
surgical group, with a median of 7.9 days (four to 
39 days) compared to 1.3 days (one to three days) in 
the percutaneous group (P  <  0.01). During follow-up, 
complete PDA occlusion was observed in all patients 
in the percutaneous group, with no changes in aortic 
or pulmonary artery flow at echocardiography. Most 
patients treated in the surgical group were followed-up 
at the services from which they were referred; thus, it 
was not possible to obtain reliable follow-up data for 
these patients.
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DISCUSSION
In this non-randomized study of two contemporary 
cohorts of patients treated in the same center, percuta-
neous closure of PDA in infants > 5 kg, children, and 
adolescents was proven to be safer than and as effective 
as surgical treatment for this condition. It is unlikely that 
the younger mean age of the surgical group impacted 
the incidence and severity of observed complications, 
because the median weight of the patients in both 
groups was similar (14  kg vs. 11.1  kg; P  =  0.052). 
Furthermore, the median age of approximately 2 years 
and weight of 11 kg of the surgical group patients are 
not usually considered risk factors for contemporary 
paediatric cardiac surgery, especially because closure 
of PDA is a technically simple surgery that does not 
require cardiopulmonary bypass. Conversely, the rela-
tively lower weight of the children in the percutaneous 
group (14 kg for children aged approximately 3 years) 
may reflect the greater hemodynamic effect of PDA in 
this group. A confounding factor in the present study 
was the larger mean diameter of the ductus arteriosus 
found in the surgical group on echocardiography. The 
authors believe that the best way to evaluate the ductus 
arteriosus is through angiography, and this procedure was 
performed only in the percutaneous group, precluding 
an accurate comparison between groups. However, it 
is likely that the higher incidence and greater severity 
of complications observed in the surgical group are 
associated with the invasive nature of cardiac surgery, 
which requires thoracotomy, rather than with the dif-
ference in mean diameter of the ductus arteriosus in 
the two groups.
The low morbidity observed in the percutaneous 
group reflects the use of a less invasive method and 
the team’s experience with this type of procedure, 
especially with regard to the selection of patients and 
the choice of size and type of device for the patient’s 
anatomy. The authors believe that the extremely low 
morbidity associated with the use of percutaneous 
treatment makes the use of an outpatient treatment 
system for patients with PDA feasible; typically, these 
patients do not require additional laboratory tests and 
can be discharged from the hospital after a brief rest 
and observation period of six to 12 hours. Wider use of 
the percutaneous procedure would result in significant 
savings of resources and would release hospital beds for 
other patients with more complex heart diseases that 
require intensive care and surgical correction.
Although a high implant success rate and a low 
incidence of complications were observed in this study, 
some qualifications should be noted. Device embolisation, 
although not observed in this series, is a complication 
that can occur during the practitioner’s learning curve 
and/or in patients who were not properly selected. The 
use of coils in PDAs with minimum diameters larger 
than 2.5-3  mm and in PDA types B and C is often 
associated with embolisation and/or malapposition.15 
The need for removal of coils that were inadequately 
positioned in three patients of this series was due to 
manufacturing defects, which were rectified, and not 
to technical errors by the surgeons or inappropriate 
patient selection. In cases of embolisation, prosthesis 
recovery in the catheterisation lab is usually possible, 
as observed in previous studies.7 Left pulmonary artery 
stenosis or coarctation of the aorta secondary to de-
vice protrusion is sometimes observed in small infants 
with large-diameter ductus arteriosus that requires the 
use of larger prostheses.16 Although this team has not 
managed patients with these characteristics, they would 
have been referred for surgical treatment in this study. 
The occurrence of pneumothorax in a patient from the 
percutaneous group can be considered a case of an 
anaesthetic complication not directly associated with 
the catheterisation procedure. In the patient in whom it 
was necessary to exchange the device for a larger one, 
ductal spasm most likely occurred prior to implantation. 
This phenomenon can occur spontaneously or secondary 
to manipulation of the ductus arteriosus with a catheter 
or guidewire prior to angiography.
The occurrence of chylothorax requiring drain -
age and prolonged hospitalisation is occasionally 
observed after surgical correction of persistent ductus 
arteriosus, as observed in three patients in this study. 
Such complications, as well as the other respiratory 
problems found in six patients in this series, result from 
the need for thoracotomy with dissection of vascular 
structures and displacement of the left lung for ligation 
or section and PDA suture. Chylothorax, which was 
observed in one patient in this series, also increases 
postoperative morbidity through its association with 
infection secondary to immunosuppression and because 
it necessitates prolonged parenteral nutrition. In this 
study, a significant number of patients required blood 
transfusion after surgery, leading to increased indirect 
costs related to the use of blood products (blood typing, 
serology). Moreover, more than half of the patients in 
this study had hypertension after surgery. This is most 
likely due to manipulation of the aorta resulting in 
adrenergic discharge and pain associated with lateral 
thoracotomy and the stretching of nerve fibres, occa-
sionally requiring the use of opioids, as observed in 
four patients in this series. Moreover, a longer hospital 
stay and a need for intensive care were observed in 
the surgical group, showing its greater morbidity. These 
needs increase hospital costs and limit the use of beds 
in the ICU and the surgical center by patients with 
complex heart diseases that require surgical correction. 
The burden imposed on healthcare systems by the 
exclusive use of surgical treatment of PDA becomes 
even more striking when the comparison is made in 
countries considered poor.17
This study found high rates of in-hospital occlu-
sion of PDA in both the percutaneous and surgically 
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treated groups. Due to the progressive endothelialisa-
tion of the device, patients in the percutaneous group 
who were discharged with minimal residual flow 
showed complete occlusion during follow-up. This 
study observed high occlusion rates with the use of 
a variety of prostheses, suggesting that physicians are 
generally successful in choosing the appropriate size 
and type of prosthesis for the underlying anatomy. 
The planning of this study and the small number of 
patients involved did not allow for the comparison of 
the performance of each available type of prosthesis. 
Additionally, follow-up data on the patients who were 
treated surgically and were discharged with minimal 
residual flow was not available; however, the fin ding 
of late residual flow after ligation of the ductus is 
not infrequent.18 
Study limitations
The most serious limitation of the present study is its 
non-randomized design. There are no non-randomized 
studies of this subject in the literature, and the perfor-
mance of such a study is extremely unlikely. Currently, 
the percutaneous approach is so well established, 
standardized, and disseminated in the major world 
centers that recruitment of patients to a surgical group 
after randomization would be difficult to justify. It ap-
pears that the surgical approach should be reserved 
for premature and small infants (<  4-5  kg) with large 
PDAs. Even in this subgroup of patients, percutaneous 
treatment has shown initial promising results.19,20
Another limitation of the current study is that it did 
not include patients with type B, C, or D PDAs, which 
are rare. In addition, the mean minimum diameter of 
the ductus arteriosus in the patients in this study was 
relatively small, restricting the ability to extrapolate 
the results to other types of anatomy and defect sizes. 
Treatment of patients with type B or C PDAs is more 
challenging and may require alternative and unusual 
techniques.21-25
The lack of outpatient follow-up of the patients 
in the surgical group, which is due to the retrospec-
tive nature of data collection in this group, is another 
limitation of this study. Conversely, although it was 
not randomized and thus introduced biases in patient 
selection, this study’s strong point is that it involved 
two practically contemporaneous cohorts, treated in 
a single hospital of excellence by experienced and 
relatively homogeneous teams, using well-established 
and standardized surgical and percutaneous techniques. 
The experience shown here most likely reflects one of 
the best clinical practices found in Brazil.
CONCLUSIONS
Based on the data presented in this paper and on 
the existing evidence in the literature regarding its safety 
and efficacy, we believe that percutaneous closure of 
PDA should be considered the treatment of choice for 
selected patients with this condition. Because the cost 
of using Gianturco coils is already covered by the SUS, 
in Brazil it seems reasonable, relevant, and urgent to 
initiate studies to evaluate the cost-effectiveness of using 
nitinol occluders (Amplatzer®, CeraTM, Lepu, Coccon, 
and Nit-Occlud®) in patients with PDAs greater than 
2.5  mm and of types B and C.
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